Authors
Jack F Price, Borah Hong, Amanda E Jacobson-Kelly, Aamir Jeewa, Kimberly Lin, Hugo Martinez, Jonathan Menachem, David Procaccini, Joseph Rossano, Vernat Exil, American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young, Pediatric Heart Failure and Transplantation Committee; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing
Published in
Circulation. Heart failure. Pages e000092. Nov 19, 2026. Epub Nov 19, 2026.
Abstract
Robust evidence from randomized controlled trials of novel heart failure medications in adults has demonstrated improved quality of life, reduced hospitalizations, and decreased mortality, informing current treatment guidelines. In contrast, data supporting the clinical benefits of newer heart failure therapies in children remain limited. To assess contemporary prescribing practices and clinician perspectives, we surveyed pediatric heart failure physicians across the United States and Canada regarding the use of angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and iron replacement therapy in children. We also reviewed the existing pediatric literature and summarized reported side effects, dosing experience, and practical guidance for the use of these therapies in the absence of rigorous evidence.
PMID:
43055105
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0